Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024530 (
malaria
)
44,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The protein kinase
Pf
CLK3 plays a critical role in the regulation of malarial parasite RNA splicing and is essential for the survival of blood stage
Plasmodium falciparum
. We recently validated
Pf
CLK3 as a drug target in
malaria
that offers prophylactic, transmission blocking, and curative potential. Herein, we describe the synthesis of our initial hit TCMDC-135051
(1)
and efforts to establish a structure-activity relationship with a 7-azaindole-based series. A total of 14 analogues were assessed in a time-resolved fluorescence energy transfer assay against the full-length recombinant protein kinase
Pf
CLK3, and 11 analogues were further assessed in asexual 3D7 (chloroquine-sensitive) strains of
P. falciparum
parasites.
SAR
relating to rings A and B was established. These data together with analysis of activity against parasites collected from patients in the field suggest that TCMDC-135051
(1)
is a promising lead compound for the development of new antimalarials with a novel mechanism of action targeting
Pf
CLK3.
...
PMID:Development of Potent
Pf
CLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. 3278 40
Malaria
is a prevalent and deadly disease. The fast emergence of drug-resistant
malaria
parasites makes the situation even worse. Thus, developing new chemical entities, preferably with novel mechanisms of action, is urgent and important. Inspired by the complex and scarce isonitrile-containing terpene natural products, we evaluated a collection of easily prepared synthetic mono- and bis-isonitrile compounds, most of which feature a simple, but rigid stilbene backbone. From this collection, potent antimalarial lead compounds with EC
50
value ranging from 27 to 88 nM against the Dd2 strain using a blood stage proliferation assay were identified. Preliminary
SAR
information showed that the isonitrile group is essential for the observed activity against the Dd2 strain and the bis-isonitrile compounds in general perform better than the corresponding mono-isonitrile compounds.
...
PMID:Natural product-inspired aryl isonitriles as a new class of antimalarial compounds against drug-resistant parasites. 3291 33
Malarial parasites employ actin dynamics for motility, and any disruption to these dynamics renders the parasites unable to effectively establish infection. Therefore, actin presents a potential target for malarial drug discovery, and naturally occurring actin inhibitors such as latrunculins are a promising starting point. However, the limited availability of the natural product and the laborious route for synthesis of latrunculins have hindered their potential development as drug candidates. In this regard, we recently described novel truncated latrunculins, with superior actin binding potency and selectivity towards P. falciparum actin than the canonical latrunculin B. In this paper, we further explore the truncated latrunculin core to summarize the
SAR
for inhibition of
malaria
motility. This study helps further understand the binding pattern of these analogues in order to develop them as drug candidates for
malaria
.
...
PMID:Structure-Activity Studies of Truncated Latrunculin Analogues with Antimalarial Activity. 3292 94
The protozoan parasite Plasmodium falciparum causes the most severe form of human
malaria
and is estimated to kill 400,000 people a year. The parasite infects and replicates in host red blood cells (RBCs), where it expresses an array of proteases to carry out multiple essential processes. We are investigating the function of falcilysin (FLN), a protease known to be required for parasite development in the RBC. We previously developed a piperazine-based hydroxamic acid scaffold to generate the first inhibitors of FLN, and the current study reports the optimization of the lead compound from that series. A range of substituents were tested at the N1 and N4 positions of the piperazine core, and inhibitors with significantly improved potency against purified FLN and cultured P. falciparum were identified. Computational studies were also performed to understand the mode of binding for these compounds, and predicted a binding model consistent with the biochemical data and the distinctive
SAR
observed at both the N1 and N4 positions.
...
PMID:Structure Guided Development of Potent Piperazine-Derived Hydroxamic Acid Inhibitors Targeting Falcilysin. 3322 14
<< Previous
1
2
3
4